hifibio-logo
  • About
  • Pipeline
  • DIS® Platform
  • Partnering
  • News
  • Join Us

News

  • About
    • Company Overview
    • Leadership
    • Scientific Advisory Board
    • Board of Directors
    • Scientific Founders
    • Contact
  • Pipeline
    • Overview
    • Overview
    • Programs
      • EMUNKITUG (HFB200301)
      • HFB200603
      • NUVUSTOTUG (HFB301001)
      • HFB200604
      • HFB3024
  • DIS® Platform
  • Partnering
  • News
  • Join Us

Latest News

Sep 25, 2025

HiFiBiO Therapeutics to Present Updated Phase 1 Clinical Data of Two Immuno-Oncology Programs at the 2025 Annual Meeting of the European Society for Medical Oncology (ESMO) 

ESMO-logo

All  Filter By:

Apr 18, 2022

Discovery of predictive biomarkers of response to T cell-targeting biologics using ex vivo single-cell profiling coupled with TCR clonotype characterization

Apr 4, 2022

HiFiBiO Therapeutics Announces Three Presentations at 2022 American Association for Cancer Research (AACR) Annual Meeting

Jan 10, 2022

HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB301001

Logo-RGB-72
Dec 20, 2021

FibroGen Exercises Exclusive License Option for HiFiBiO’s CCR8 Program

Nov 1, 2021

HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200301

< 1 … 5 6 7 8 9 … 18 >

oncoverity logo

© 2025 HiFiBiO Therapeutics, Inc.
All Rights Reserved.

Contact

contact@hifibio.com 237 Putnam Ave
Cambridge, MA 02139

Follow Us

Legal

Privacy Policy
Disclaimer
logo
  • About
    • Company Overview
    • Leadership
    • Scientific Advisory Board
    • Board of Directors
    • Scientific Founders
    • Contact
  • Pipeline
    • Overview
    • Overview
    • Programs
      • EMUNKITUG (HFB200301)
      • HFB200603
      • NUVUSTOTUG (HFB301001)
      • HFB200604
      • HFB3024
  • DIS® Platform
  • Partnering
  • News
  • Join Us